Last reviewed · How we verify

NCT06376461: GUTPHOS

Prospective, Multicentre Study to Validate the GastroIntestinal Dysfunction Score (GIDS) and Describe Prevalence, Outcomes, and Management of Phosphate Disorders in Intensive Care Patients

Completed Last updated 3 July 2025
What this trial tests

trial testing Data collection in Gastrointestinal Dysfunction in 92 participants. Completed in 26 June 2025.

Timeline
26 July 2024
Primary endpoint
31 March 2025
26 June 2025

Quick facts

Lead sponsorUniversity Hospitals of North Midlands NHS Trust
StatusCompleted
Study typeOBSERVATIONAL
Enrollment92
Start date26 July 2024
Primary completion31 March 2025
Estimated completion26 June 2025
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University Hospitals of North Midlands NHS Trust

Who can join

18 and older, any sex, with Gastrointestinal Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Part A Multiple organ dysfunction syndrome is one of the main problems in critically ill patients. Several organ dysfunctions are routinely and systematically monitored in patients admitted to intensive care units. Gastrointestinal dysfunction is currently not included in multiple organ dysfunction scores and lacks a standardised approach. At the same time, investigators earlier studies have shown that gastrointestinal dysfunction plays an essential role in the course of illness in intensive care patients. A tool for measuring dysfunction is needed to enable future studies on interventions to improve gastrointestinal function. The GIDS (GastroIntestinal Dysfunction Score) combines different clinical signs and symptoms commonly observed and documented in patients in the ICU into a scoring system, allowing distinguishing between different grades of severity of dysfunction. The investigators will only use observations documented during the patient's stay in the intensive care unit without additional measurements and calculate gastrointestinal (GIDS) and other organ dysfunction scores. Part B Phosphate is an electrolyte commonly measured and often corrected, while the indications and clear guidance for correction are insufficiently studied. The results of this study will assist in specifying indications for the correction of phosphate levels better and refine the management strategies in the future. Only phosphate levels measured as part of routine care will be documented, no additional samples for study purposes will be taken, and the study will not influence the treatment of phosphate disorders.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Hypophosphataemia in Critical Illness: A Narrative Review.
    Ramanan M, Tabah A, Affleck J, Edwards F, et al · · 2024 · cited 3× · PMID 39685625 · DOI 10.3390/jcm13237165

Verify or expand the search:

Other trials of Data collection

Trials testing the same drug.

Other recruiting trials for Gastrointestinal Dysfunction

Currently open trials in the same condition.

Other University Hospitals of North Midlands NHS Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06376461.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing